KRAS and pancreatic ductal adenocarcinoma: By constructing a genetically engineered pancreatic ductal adenocarcinoma mouse model via conditional expression of oncogenic Kras and deletion of the catalytic domain of RNF43, loss of RNF43 promotes pancreatic ductal adenocarcinoma tumorigenesis, and contributes to decreased survival time of mice [13].